Biotech and Pharma Shares Drop as Investors Shift Focus to Energy Sector
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Source: Barron's
Biotech and Drug Stocks Performance: A significant increase in biotech and drug stock valuations occurred in the latter half of 2025, but signs of instability emerged recently.
Investor Behavior Shift: Investors are currently shifting their focus and capital towards energy shares.
Impact of U.S. Operations: The U.S. operation to seize Venezuelan President Nicolás Maduro has influenced market dynamics, particularly in the energy sector.
Market Volatility: The overall market is experiencing volatility as sectors react to geopolitical events and investor sentiment changes.
Analyst Views on XBI
Wall Street analysts forecast XBI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XBI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 128.180
Low
Averages
High
Current: 128.180
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
